Immune response to Escherichia coli antigens entrapped in liposomes. I. Immunopathological studies.
In this study, we have searched for an effective mucosal delivery system for a purified E. coli antigen which elicits anticolonization and anti-toxic immunity. E. coli colonization factor antigen (CFA/I) and heat-labile enterotoxin (LT) were encapsulated in liposomes. To determine the efficacies of soluble and liposome-encapsulated E. coli antigens young rabbits were mucosally treated with three oral doses of E. coli antigens given 7 days apart. Ten days after the last booster, rabbits were orally challenged with 5 x 10(9) bacterial cells (O78:H11 serotype). The experimental results allow of making some remarks which can be correlated with the protection obtained in vaccinated animals: (a) immunization with E. coli antigens entrapped in liposomes ensured protection against ETEC strains; (b) lower protection against homologous and heterologous CFA/I +(LT- ST+) strains were noticed; (c) adhesion of labelled -3H-leucine-bacteria to the intestinal mucosa revealed a maximum distribution in duodenum-jejunum and minimum in the colonic mucosa; (d) it contributed to the release of inoculated virulent bacteria from intestinal tract; (e) humoral, cellular and histopathological findings confirm the afore mentioned observation. Summing up, these results suggest that liposomes are very good carriers for E. coli antigens and these findings highlight the potential use of LT and CFA/I antigens entrapped in liposomes as mucosal and humoral induction of immune response and make them a candidate for future use in prophylaxis of diarrhoea in man.
Dima
V F
VF
Cantacuzino Institute, Bucharest, Romania.
Popescu
C
C
Postoarcă
A
A
Ionescu
M D
MD
Oproiu
G
G
Lacky
D
D
Balotescu
C
C
Dima
S V
SV
D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis*; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D001422:Bacterial Adhesion; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000276:immunology; D003967:Diarrhea / Q000517:prevention & control; D004337:Drug Carriers; D004768:Enterotoxins / Q000008:administration & dosage / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000517:prevention & control*; D029968:Escherichia coli Proteins; D005243:Feces / Q000382:microbiology; D036781:Fimbriae Proteins; D007413:Intestinal Mucosa / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D008081:Liposomes; D010581:Peyer's Patches / Q000276:immunology; D011817:Rabbits; D013154:Spleen / Q000276:immunology; D014611:Vaccination / Q000379:methods*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004337:Drug Carriers; D004768:Enterotoxins; D029968:Escherichia coli Proteins; D008081:Liposomes; C022924:colonization factor antigens; D036781:Fimbriae Proteins; C027538:heat-labile enterotoxin, E coli